---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-25-002131"
form_type: "8-K"
ticker: "PHIO"
cik: "0001533040"
company_name: "Phio Pharmaceuticals Corp."
filed_at: "2025-03-31T23:59:59+00:00"
generated_at: "2026-05-24T01:45:16.455486+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Phio Pharma FY24 net loss $7.2M; PH-762 Phase 1b with complete responses; $12.1M raised

## Summary
- Net loss for FY24 was $7.2M ($9.08/share), down from $10.8M ($46.76/share) in FY23.
- Cash at Dec 31, 2024 was $5.4M; subsequent financings added net $6.8M, total $12.1M raised.
- PH-762 Phase 1b: 3rd cohort fully enrolled; in cohort 2, 2 complete responses and 1 partial response out of 4 patients.
- R&D expenses decreased 42% to $3.7M due to cost rationalization and termination of AgonOx agreement.
- Total proceeds of $9.2M from registered direct offerings and $2.9M from warrant exercises.

## SEC filing metadata
- accession: 0001683168-25-002131
- form_type: 8-K
- ticker: PHIO
- cik: 0001533040
- company_name: Phio Pharmaceuticals Corp.
- filed_at: 2025-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1533040/000168316825002131/0001683168-25-002131-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1533040/000168316825002131/phio_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-25-002131
- JSON: https://secwatch.observer/filing/0001683168-25-002131.json
- Plain text: https://secwatch.observer/filing/0001683168-25-002131.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.